Posts

2025 FDA staff cuts and their impact on new drug review timelines

FDA Pushes for Onshoring and Improved Data Fidelity in Generic Drug User Fee (GDUFA IV) Negotiations

RFK Jr.'s FDA staff cuts claimed key user fee negotiators, threatening renewal talks with pharma: Reuters

Massive FDA Staff Cuts Jeopardize Drug and Device Review Processes, Threatening Critical User Fee Programs